Recombinant human endostatin - Jiangsu Wuzhong Pharmaceutical

Drug Profile

Recombinant human endostatin - Jiangsu Wuzhong Pharmaceutical

Alternative Names: Sulijia

Latest Information Update: 27 Apr 2017

Price : $50

At a glance

  • Originator Jiangsu Wuzhong Pharmaceutical Group
  • Class Angiostatic proteins; Antineoplastics; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 17 Jan 2017 Jiangsu Wuzhong Pharmaceutical completes a phase III trial in Non-small cell lung cancer in China (NCT03117335)
  • 15 Mar 2016 Biomarkers information updated
  • 10 Nov 2011 Phase-III clinical trials for Non-small cell lung cancer (Combination therapy, Metastatic disease) in China (IV) (NCT03117335)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top